Mario Sznol

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 24

Top Topics

Advanced Cancer

Systematic Review

Natural Killer Cells

Renal Cell Carcinoma

Top Venues

Journal for immunotherapy of cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature communications

BMJ open ophthalmology

This page only lists publications with an associated author ORCID identifier.

Publications

David S Hong, Patricia LoRusso, Mario Sznol
A crisis in clinical research. Journal for immunotherapy of cancer 12 (7) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
David S Hong, Patricia LoRusso, Mario Sznol
A crisis in clinical research. Journal for immunotherapy of cancer 12 (7) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
David S Hong, Patricia LoRusso, Mario Sznol
A crisis in clinical research. Journal for immunotherapy of cancer 12 (7) (2024)
Sarah A Weiss, Mario Sznol, Montaser Shaheen, Miguel-Angel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodriguez Abreu, Valentina Boni, Lynn M Schuchter, Maria Gonzales Cao, Ana M Arance, Wei Wei, Apar Kishor Ganti, Ralph J Hauke, Alfonso Berrocal, Nicholas O Iannotti, Frank J Hsu, Harriet M Kluger
A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Adi Diab, Helen J Gogas, Shahneen Sandhu, Georgina V Long, Paolo Antonio Ascierto, James M G Larkin, Mario Sznol, Fabio Franke, Tudor E Ciuleanu, Caio Pereira, Eva Muñoz Couselo, Fernanda Bronzon Damian, Michael Schenker, Aldo Perfetti, Celeste Lebbè, Gaëlle Quéreux, Friedegund Meier, Brendan D Curti, Carlos Rojas, Yull Arriaga, Haisu Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary A Tagliaferri, Nikhil I Khushalani
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Mario Sznol, Naiyer Rizvi
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. Journal for immunotherapy of cancer 11 (1) (2023)
Julius Strauss, Jean-Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K Pachynski, Theodore S Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom, Renee N Donahue, Yo-Ting Tsai, XiaoZhe Wang, Yulia Vugmeyster, Frank Beier, Joerg Seebeck, Andreas Schroeder, Sarah Chennoufi, James L Gulley
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. Journal for immunotherapy of cancer 11 (5) (2023)
Brooke Horowitch, Daniel Y Lee, Min Ding, Sandra Martinez-Morilla, Thazin Nwe Aung, Feriel Ouerghi, Xueting Wang, Wei Wei, William E Damsky, Mario Sznol, Harriet M Kluger, David L Rimm, Jeffrey Ishizuka
Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Mario Sznol, Naiyer Rizvi
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. Journal for immunotherapy of cancer 11 (1) (2023)
Adriana M Kahn, Curtis J Perry, Katrina Etts, Harriet Kluger, Mario Sznol
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The oncologist (2023)
Noah J Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, Antonella Bacchiocchi, David Y Chen, Mario Sznol, Ruth Halaban, Aadel A Chaudhuri, Aaron M Newman
CD4 T cells and toxicity from immune checkpoint blockade. Immunological reviews (2023)
Mario Sznol, Naiyer Rizvi
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. Journal for immunotherapy of cancer 11 (1) (2023)
Mario Sznol, Naiyer Rizvi
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. Journal for immunotherapy of cancer 11 (1) (2023)
Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James R Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan, James Clune, Kelly Olino, Laxmi Parida, Joerg Nikolaus, Meiling Zhang, Shuang Zhao, Yan Wang, Gang Huang, Miaojian Wan, Xianan Li, Jian Cao, Qin Yan, Xiang Chen, Aaron M Newman, Ruth Halaban
Author Correction: Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nature communications 13 (1) (2022)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Michael R Bishop, Daniel C Chen, Madhav Dhodapkar, Leisha A Emens, Marc S Ernstoff, Matthew J Ferris, Tim F Greten, James L Gulley, Roy S Herbst, Rachel W Humphrey, James Larkin, Kim A Margolin, Luca Mazzarella, Suresh S Ramalingam, Meredith M Regan, Brian I Rini, Mario Sznol
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for immunotherapy of cancer 10 (9) (2022)
Jacob S Heng, Jenna M Kim, D Kyle Jones, Kathleen M Stoessel, Sarah A Weiss, Mario Sznol, Harriet M Kluger, Scott D Walter, Niki A Silverstein, Renelle Pointdujour-Lim
Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. BMJ open ophthalmology 7 (1) (2022)
Alexander X Lozano, Aadel A Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E Turner, Chloé Beate Steen, Bogdan A Luca, Ti Badri, Gunsagar S Gulati, Milad R Vahid, Farnaz Khameneh, Peter K Harris, David Y Chen, Kavita Dhodapkar, Mario Sznol, Ruth Halaban, Aaron M Newman
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nature medicine 28 (2) (2022)
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet Asim Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Jonathan Zalevsky, Arlene O Siefker-Radtke, Michael E Hurwitz
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Journal for immunotherapy of cancer 10 (4) (2022)
Farshad Farshidfar, Kahn Rhrissorrakrai, Chaya Levovitz, Cong Peng, James R Knight, Antonella Bacchiocchi, Juan Su, Mingzhu Yin, Mario Sznol, Stephan Ariyan, James Clune, Kelly Olino, Laxmi Parida, Joerg Nikolaus, Meiling Zhang, Shuang Zhao, Yan Wang, Gang Huang, Miaojian Wan, Xianan Li, Jian Cao, Qin Yan, Xiang Chen, Aaron M Newman, Ruth Halaban
Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nature communications 13 (1) (2022)
Petra Ross-MacDonald, Alice M Walsh, Scott D Chasalow, Ron Ammar, Simon Papillon-Cavanagh, Peter M Szabo, Toni K Choueiri, Mario Sznol, Megan Wind-Rotolo
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. Journal for immunotherapy of cancer 9 (3) (2021)
Nikhil I Khushalani, Adi Diab, Paolo Antonio Ascierto, James M G Larkin, Shahneen Sandhu, Mario Sznol, Henry B Koon, Anthony Jarkowski, Paul Statkevich, Paul Statkevich, William J Geese, Georgina V Long
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future oncology (London, England) 16 (28) (2020)